Found: 3
Select item for more details and to access through your institution.
Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial.
- Published in:
- Oncologist, 2023, v. 28, n. 12, p. e1259, doi. 10.1093/oncolo/oyad163
- By:
- Publication type:
- Article
Effects of AgRP Inhibition on Energy Balance and Metabolism in Rodent Models.
- Published in:
- PLoS ONE, 2013, v. 8, n. 6, p. 1, doi. 10.1371/journal.pone.0065317
- By:
- Publication type:
- Article
A phase 1 dose‐escalation study of the poly(ADP‐ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 7, p. 1041, doi. 10.1002/cncr.34662
- By:
- Publication type:
- Article